Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

28 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prognosis of children with mixed phenotype acute leukemia treated on the basis of consistent immunophenotypic criteria.
Mejstrikova E, Volejnikova J, Fronkova E, Zdrahalova K, Kalina T, Sterba J, Jabali Y, Mihal V, Blazek B, Cerna Z, Prochazkova D, Hak J, Zemanova Z, Jarosova M, Oltova A, Sedlacek P, Schwarz J, Zuna J, Trka J, Stary J, Hrusak O. Mejstrikova E, et al. Among authors: oltova a. Haematologica. 2010 Jun;95(6):928-35. doi: 10.3324/haematol.2009.014506. Epub 2010 Feb 9. Haematologica. 2010. PMID: 20145275 Free PMC article.
Complex karyotype and translocation t(4;14) define patients with high-risk newly diagnosed multiple myeloma: results of CMG2002 trial.
Nemec P, Zemanova Z, Kuglik P, Michalova K, Tajtlova J, Kaisarova P, Oltova A, Filkova H, Holzerova M, Balcarkova J, Jarosova M, Rabasova J, Hruba M, Spicka I, Gregora E, Adam Z, Scudla V, Maisnar V, Schutzova M, Hajek R; Czech Myeloma Group. Nemec P, et al. Among authors: oltova a. Leuk Lymphoma. 2012 May;53(5):920-7. doi: 10.3109/10428194.2011.634042. Epub 2011 Dec 13. Leuk Lymphoma. 2012. PMID: 22023516 Clinical Trial.
Chromosome 6q deletion correlates with poor prognosis and low relative expression of FOXO3 in chronic lymphocytic leukemia patients.
Jarosova M, Hruba M, Oltova A, Plevova K, Kruzova L, Kriegova E, Fillerova R, Koritakova E, Doubek M, Lysak D, Prochazka V, Mraz M, Indrak K, Papajik T. Jarosova M, et al. Among authors: oltova a. Am J Hematol. 2017 Oct;92(10):E604-E607. doi: 10.1002/ajh.24852. Epub 2017 Jul 29. Am J Hematol. 2017. PMID: 28699185 Free article. No abstract available.
Novel CHK1 inhibitor MU380 exhibits significant single-agent activity in TP53-mutated chronic lymphocytic leukemia cells.
Boudny M, Zemanova J, Khirsariya P, Borsky M, Verner J, Cerna J, Oltova A, Seda V, Mraz M, Jaros J, Jaskova Z, Spunarova M, Brychtova Y, Soucek K, Drapela S, Kasparkova M, Mayer J, Paruch K, Trbusek M. Boudny M, et al. Among authors: oltova a. Haematologica. 2019 Dec;104(12):2443-2455. doi: 10.3324/haematol.2018.203430. Epub 2019 Apr 11. Haematologica. 2019. PMID: 30975914 Free PMC article.
Imatinib as the first-line treatment of patients with chronic myeloid leukemia diagnosed in the chronic phase: can we compare real life data to the results from clinical trials?
Zackova D, Klamova H, Dusek L, Muzik J, Polakova KM, Moravcova J, Jurcek T, Dvorakova D, Racil Z, Pospisil Z, Oltova A, Michalova K, Brezinova J, Razga F, Doubek M, Cetkovsky P, Trneny M, Mayer J. Zackova D, et al. Among authors: oltova a. Am J Hematol. 2011 Mar;86(3):318-21. doi: 10.1002/ajh.21942. Epub 2011 Feb 15. Am J Hematol. 2011. PMID: 21328429 Free article. No abstract available.
28 results